Insulet develops, manufactures, and markets the Omnipod Insulin Management System for people that have diabetes. This system ...

Insulet Corporation (PODD), headquartered in Acton, Massachusetts, operates as an innovative medical device company. Valued ...

Insulet (NASDAQ:PODD – Get Free Report) was upgraded by StockNews.com from a “hold” rating to a “buy” rating in a research ...

Insulet Corp. closed 7.87% below its 52-week high of $289.46, which the company achieved on February 7th.

Insulin delivery company Insulet Corporation (NASDAQ:PODD) reported Q4 CY2024 results , with sales up 17.2% year on year to ...

Stock analysts at Leerink Partnrs lowered their Q1 2025 earnings per share (EPS) estimates for Insulet in a research note ...

Insulet Corporation (NASDAQ:PODD) reported fourth-quarter adjusted EPS of $1.15, down from $1.40 a year ago but beating the ...

Insulet's impressive growth with its Omnipod system, robust 2024 results, and surging valuation make it attractive. See more ...

Insulet (PODD) came out with quarterly earnings of $1.15 per share, beating the Zacks Consensus Estimate of $1.05 per share. This compares to earnings of $1.40 per share a year ago. These figures ...

Insulet (PODD) reported $597.5 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 17.2%. EPS of $1.15 for the same period compares to $1.40 a year ago.